• Rheumatology/Psoriatic Arthritis Edition: Top Headlines for Week of July 22, 2024

  • Jul 25 2024
  • Duración: 11 m
  • Podcast

Rheumatology/Psoriatic Arthritis Edition: Top Headlines for Week of July 22, 2024

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • In this edition, guselkumab brings ‘stringent’ control through 2 years, SARDs outpatient visits result in opioid prescriptions and more.

    Read the full coverage here:

    Guselkumab brings active psoriatic arthritis into ‘stringent’ control through 2 years

    Nearly one-quarter of all SARDs outpatient visits in US result in opioid prescription

    FDA approves biosimilar Pyzchiva for all approved Stelara indications

    Tofacitinib effective for juvenile idiopathic arthritis through 4 years

    Bimekizumab results in rapid, sustained improvements to PsA patient reported outcomes

    References:

    Brunner HI, et al. Ann Rheum Dis. 2024;doi:10.1136/ard-2023-225094.

    Gossec L, et al. Rheumatology. 2024;doi:10.1093/rheumatology/keae277.

    Huang Y, et al. Arthritis Care Res. 2024;doi:10.1002/acr.25378.

    Press Release

    Ritchlin CT, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-06991-8.
    Más Menos
Más Menos

Lo que los oyentes dicen sobre Rheumatology/Psoriatic Arthritis Edition: Top Headlines for Week of July 22, 2024

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles